Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02484261 |
Recruitment Status :
Terminated
(Contractual/Funding/Accrual)
First Posted : June 29, 2015
Last Update Posted : April 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leukemia | Drug: Bortezomib Drug: Pravastatin | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | Non-Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children |
Study Start Date : | May 2015 |
Actual Primary Completion Date : | May 18, 2018 |
Arm | Intervention/treatment |
---|---|
No Intervention: Monitoring phase
Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
|
|
Experimental: Treatment phase
Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
|
Drug: Bortezomib
1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
Other Name: Velcade Drug: Pravastatin 10 mg for age < 8 years, 20 mg for age 8-<13 years, 40 mg for ages >14 years |
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 3 years ]Tolerability of bortezomib and pravastatin in pediatric relapsed leukemia patients following allogeneic transplantation
- Number of relapses that are detected by CD34+ chimerism before clinical symptoms [ Time Frame: 3 years ]The sensitivity of detection of recurrent acute leukemia in pediatric patients by peripheral blood CD34+ chimerism in pediatric patients following allogeneic HSCT
- The number of patients who respond to bortezomib and pravastatin treatment for relapsed acute leukemia as defined by those that achieve complete response, partial response or stable disease [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Months to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria to enter study:
- Voluntary written informed consent by patient or legal guardian (as appropriate) before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
-
Female patients who:
- Are postmenopausal for at least 1 year before the Screening visit, OR
- Are surgically sterile, OR
- If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse
OR Male patients, even if surgically sterilized (i.e., status postvasectomy), who:
- Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, OR
-
Agree to completely abstain from heterosexual intercourse
- Lansky(if age <15)/Karnofsky (if age >16 yr) performance status > 50%
- Hepatic function: total bilirubin ≤ 2.5 mg/dl, and ALT/AST < or equal to 5 x the upper limit of normal
- Renal function: Creatinine clearance > 60 ml/min/1.73 m2 (as determined by 24 hour collection or nuclear (glomerular filtration rate) GFR or Cystatin C calculation)
- Cardiac function: LVEF > 50% or LVSF > 27%
- Pulmonary function tests: DLCO and FEV1 > 50% (if able to perform PFTs, if not able to perform PFTs SAO2> 94% on room air).
- Acute leukemia or Myelodysplastic syndrome (MDS)
Inclusion Criteria to initiate therapy with bortezomib and pravastatin
- Lansky performance status (if age < 15) /Karnofsky (if age >16 yr) performance status > 50%
- Hepatic function: total bilirubin ≤ 2.5 mg/dl, and ALT/AST < or equal to 5 x the upper limit of normal (ULN)
- Renal function: Cr < ULN for age
- Relapse of systemic disease documented by any of the following: morphology, flow cytometry, cytogenetics and/or FISH.
- Patient has a platelet count of more than 20,000/μL within 7 days before enrollment. Patients may be transfused prior to this evaluation but may not be platelet refractory at enrollment.
- Patient has an absolute neutrophil count of greater than 500 /μL within 7 days before enrollment.
- Patients with confirmed relapse post-HSCT who were not previously enrolled on monitoring portion of protocol, will also be eligible to enroll and receive novel combination if entry criteria met at time of relapse.
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be treated on the study:
- Patient has greater than or equal to Grade 2 peripheral neuropathy
- Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
- Patient has hypersensitivity to bortezomib, boron, or mannitol.
- Female patients who are lactating or pregnant.
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Evidence of residual or relapse of another malignancy(other than the hematological malignancy which is the indication for stem cell transplant)at the time of transplant preparative regimen initiation
- Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of bortezomib/pravastatin and throughout the duration of therapy.
- Radiation therapy within 3 weeks before start of bortezomib/pravastatin. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02484261
United States, District of Columbia | |
Children's National Medical Center | |
Washington, District of Columbia, United States, 20010 |
Principal Investigator: | Reuven Schore, MD | Children's National Research Institute |
Responsible Party: | Reuven Schore, MD, Children's National Research Institute |
ClinicalTrials.gov Identifier: | NCT02484261 |
Other Study ID Numbers: |
Pro00004062 |
First Posted: | June 29, 2015 Key Record Dates |
Last Update Posted: | April 6, 2021 |
Last Verified: | April 2021 |
childhood leukemia relapsed leukemia Hematopoietic Stem Cell Transplantation |
Leukemia Neoplasms by Histologic Type Neoplasms Bortezomib Pravastatin Antineoplastic Agents Anticholesteremic Agents |
Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |